Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04833036
Recruitment Status : Unknown
Verified April 2021 by Weijian Guo, Fudan University.
Recruitment status was:  Recruiting
First Posted : April 6, 2021
Last Update Posted : April 6, 2021
Information provided by (Responsible Party):
Weijian Guo, Fudan University

Brief Summary:
The primary endpoint is to evaluate the progression-free survival (PFS).

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: Irinotecan Drug: cetuximab Phase 2

Detailed Description:
This study was designed for patients with advanced bowel cancer after first-line LOHP and 5-FU treatment failure. The control group was treated with second-line CPT-11+C225. The study group used second-line CPT-11 single drug until the third line was CPT-11+C225. treatment. Referring to the previous literature data, the PFS of the second-line treatment of CPT-11+C225 is about 4 months. This study assumes that the total PFS time of C225 can be extended to 7 months after the failure of second-line CPT-11 treatment compared with the direct second-line combination. , set α = 0.05, β = 0.2, the expected enrollment time is 2 years, the follow-up time is 1 year, the 10% sample shedding rate, the total sample size is about 60 cases per group, a total of 120 cases.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Second-line Irinotecan Combined With Cetuximab (c-CetuIRI) Versus Second-line Irinotecan Three-line Irinotecan Plus Cetuximab (s-IRI-CetuIRI) in the Treatment of Oxaliplatin and 5-FU Phase II Clinical Study of Wild-type Advanced Colorectal Cancer With RAS Gene
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: c-CetuIRI
Irinotecan combined with cetuximab
Drug: Irinotecan
180 mg/m2, ivgtt d1,q2w

Drug: cetuximab
500 mg/m2, ivgtt d1,q2w

Experimental: s-IRI-CetuIRI
single irinotecan first, then irinotecan plus cetuximab sequentially after PD
Drug: Irinotecan
180 mg/m2, ivgtt d1,q2w

Drug: cetuximab
500 mg/m2, ivgtt d1,q2w

Primary Outcome Measures :
  1. PFS [ Time Frame: up to 8 weeks ]
    progression free survival

Secondary Outcome Measures :
  1. OS [ Time Frame: through study completion, an average of half year ]
    overall survival

  2. ORR [ Time Frame: up to 8 weeks ]
    objective response rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signing informed consent;
  2. Age is greater than or equal to 18 years old;
  3. Metastatic colorectal adenocarcinoma confirmed by tissue or cytopathology;
  4. First-line failure to use oxaliplatin combined with fluorouracil (with or without anti-angiogenic targeting drugs);
  5. One or more measurable lesions, the longest diameter of the spiral CT scan is at least 10 mm, and the diameter of the conventional CT scan is at least 20 mm (the solid tumor efficacy evaluation standard, RECIST standard, version 1.1);
  6. The Eastern Cancer Cooperative Group (ECOG) has a general status score of 0-2;
  7. The bone marrow capacity, liver and kidney function reached the following criteria within 7 days before screening:

    Absolute neutrophil count ≥ 1.5x109 / L; hemoglobin ≥ 9.0 g / dl; platelet count ≥ 80 x 109 / L; total bilirubin ≤ 1.5 times normal upper limit (ULN); alanine aminotransferase and aspartate aminotransferase ≤ 2.5 x ULN Alkaline phosphatase ≤ 3 x ULN; serum creatinine ≤ 1.5 x ULN;

  8. Women of childbearing age need to take effective contraception.
  9. RAS, B-RAF gene wild type

Exclusion Criteria:

  1. Previous use of irinotecan or anti-egfr therapy for advanced colorectal cancer (e.g. Cetuximab, panizumab, etc.);
  2. History of HIV infection or active chronic hepatitis b or c (high copy viral DNA);
  3. Patients with important organ failure or other important diseases: patients with serious heart disease including congestive heart failure, uncontrolled arrhythmia, angina requiring long-term medication, heart valve disease, myocardial infarction, pericardial effusion with obvious symptoms, and refractory hypertension;A history of severe neurological or psychiatric problems;Severe infection;Active disseminated intravascular coagulation
  4. Active severe clinical infection;
  5. Symptomatic brain or meningeal metastasis (unless the patient was treated for > for 6 months, had negative imaging results within 4 weeks prior to study entry, and had stable tumour-related clinical symptoms at study entry);
  6. Patients whose seizures require treatment (e.g. steroids or antiepileptic therapy);
  7. Receiving renal dialysis;
  8. Have a history of other malignant tumors within 5 years, except for cured cervical carcinoma in situ or skin basal cell carcinoma, except for those whose metastasis can be confirmed by pathology to be from other tumor sources;
  9. Chronic intestinal diseases, infectious intestinal diseases and intestinal obstruction;
  10. Drug abuse and medical, psychological or social conditions may interfere with patients' participation in studies or affect the assessment of their findings;
  11. Any unstable condition or condition that may endanger the safety and compliance of patients;
  12. Pregnant or lactating women;Having fertility but not taking adequate contraceptive measures;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04833036

Layout table for location contacts
Contact: Weijian Guo, Professor 86-21-64175590

Layout table for location information
China, Shanghai
Fudan University Cancer Hospital Recruiting
ShangHai, Shanghai, China, 200032
Contact: Wei Jian Guo    13816066360   
Sponsors and Collaborators
Fudan University
Layout table for additonal information
Responsible Party: Weijian Guo, professor, Fudan University Identifier: NCT04833036    
Other Study ID Numbers: Cetu-IRI
First Posted: April 6, 2021    Key Record Dates
Last Update Posted: April 6, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Weijian Guo, Fudan University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Immunological